April 24, 2019
Macrogen and Exosome Plus to Jointly Develop Exosome-based Diagnostic and Treatment Solutions
Exosome Plus will exclusively supplyits high-efficiency exosome isolation kit ‘Exo2DTM’ toMacrogen for one year.
Pharmaceuticals, Biotechnology and Life Sciences
Author: BusinessWire
April 24, 2019
Aptorum Group Establishes Smart Pharma to Focus on Computational Repurposed Drug Discovery for Orphan and Unmet Diseases
Aptorum Group Limited has established new subsidiary group, Smart Pharma
April 24, 2019
Aptorum Group’s Smart Pharma announces launch of its asset backed Smart Pharma token (SMPT), supported by its computational repurposed drug discovery platform Smart-ACT™
SMPT token holder will allow them to benefit from the inherent valuationgrowth of SPLP’s intellectual property portfolio
April 24, 2019
Teva drops clinical development program for use of fremanezumab in episodic cluster headache
Teva is discontinuing the clinical developmentprogram for use of fremanezumab in cluster headaches.
April 24, 2019
Rexgenero Presents Update on Phase III Clinical Trials with REX-001, a Cell-based Therapy for Critical Limb Ischaemia
Rexgenero presented an update on its two Phase III SALAMANDER trials beingconducted across Europe for its lead development programme REX-001 totreat CLI in patients with diabetes.
April 24, 2019
FSD Pharma Announces Share Exchange Transaction with Aura Health
– Intended Transaction positions FSD to establish distribution channel in Germany & Eurozone – TORONTO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/FSDDF?src=hash" target="_blank"gt;#FSDDFlt;/agt;–FSD Pharma Inc.…
April 24, 2019
Bicycle Therapeutics to Present Immune Oncology CD137 Data on Multivalent and Tumour-targeted Bispecific Bicycles at Peptides Congress
Punit Upadhyaya, Ph.D., SeniorScientist at Bicycle, will present at the 6th Annual PeptidesCongress in London.
April 24, 2019
Aptorum Group Limited Announces Repurchase of USD13,500,000 Outstanding Convertible Bonds Due 2019
HONG KONG–(BUSINESS WIRE)–Aptorum Group Limited (NASDAQ: APM) (“Aptorum” or the “Company”), a pharmaceutical company focused on the development and commercialization…
April 24, 2019
Ipsen Reports Strong Double-Digit Sales Growth in First Quarter 2019 and Confirms Full Year 2019 Financial Targets
Ipsen Q1 2019 sales growth of 17.0% as reported, or 15.8%1at constant exchange rates and consolidation scope.
April 24, 2019
EpimAb Biotherapeutics is Granted US Patent on Core Bispecific Antibody Technology
Based on EpimAb’sglobally filed first application, this patent broadly covers bispecificantibodies obtained utilizing the company’s FIT-Ig®technology in a composition of matter claim.